Year: 2021

Several lenders in the industry offer unique loan products to meet the changing demands of the consumers. If you are looking for a loan with high amount and low interest, you can consider Hero FinCorp mortgage loan. Hero FinCorp is one of the biggest and the most reliable lenders in the country and they have built a solid presence across the length and breadth of the country. No matter the purpose of borrowing, you can apply for a loan that serves your needs and is easy to repay. A mortgage loan is a secured loan where you hypothecate an asset with the lender to avail funds. It is a very popular form of borrowing and is the first choice of several business owners in the country. If you own an asset, you can apply for a loan by hypothecating it. The asset could be a residential or commercial property and it should not be hypothecated anywhere...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Senior Management and invited guests will host a virtual Oncology R&D Day. Updates from today’s talk will include:Overview of clinical strategy and corporate outlook 2022 and beyondPatrick Amstutz, PhD, CEO of Molecular PartnersUpdate and status of Abicipar- investigational anti-VEGF for the treatment of nAMD and DMEMichael Stumpp, PhD, COO of Molecular PartnersDARPin applications and technological advancementsDaniel Steiner, PhD, SVP ResearchMultispecific immune cell engagers, Targeting CD40 and 4-1bb in combination with Fibroblast Activation...

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 10, 2021, indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 25%, holding 6,500,000 shares, i.e. 28.77% of Celyad Oncology’s shares and 26.04% voting rights as of December 8, 2021. Content of the Notification:Reason of the Notification:Upward crossing of the 25% thresholdAcquisition of voting securities or voting rightsNotification by:A parent undertaking or a controlling personPersons subject to the notification requirement:Fortress...

ROTTERDAM, The Netherlands (15 December 2021) – IMCD N.V. today announces that its Supervisory Board has nominated the current members of the Management Board for reappointment. Both nominations will be put before shareholders for approval at the next Annual General Meeting of IMCD N.V. scheduled for 2 May 2022. The Supervisory Board nominates Piet van der Slikke (CEO) for a new term of two years as of the next AGM in 2022, as he has informed the Supervisory Board of his intention to retire from the Management Board in the course of 2024. This is in line with the overall succession strategy in place. Hans Kooijmans (CFO) is nominated for another term of four years as of the next AGM in 2022. In addition to the nomination of the Management Board members, the Supervisory Board has also nominated Mr. Stephan Nanninga for a second term of...

As of 4 January 2022, Paul Horner will become a member of the Board of Directors of LHV UK Limited, a subsidiary of AS LHV Group. He will be the first Independent Non-Executive Director on the Board of Directors of LHV UK Limited. Paul Horner will also become the Chair of the Risk Committee, a member of the Audit Committee and a member of the Nominations Committee of LHV UK Limited. Paul Horner was born in 1962. He graduated with M.A. Honours from the University of Oxford in 1983 and is an Associate of the UK Chartered Institute of Bankers. Paul Horner has gained extensive experience of General and Risk Management in Retail, Commercial, Investment and Private Banking across various international markets. He joined Barclays in 1988 and held various Executive and Risk Management roles there. In 2003 he joined The Royal Bank of Scotland Group....

MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) — Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the pricing of its upsized initial public offering of 2.4 million American Depositary Shares, or ADSs, each representing one ordinary share, at a public offering price of $11.50 per share. Genenta also sold 720,114 ordinary shares reserved for subscription by its existing shareholders at a price of $11.50 per share. The gross proceeds from the offering, including ordinary shares, are expected to be approximately $36 million before deducting underwriting and advisory fees and offering expenses. In addition, Genenta has granted the underwriters...